{"url_path":"/sec/bcda/8-k/2026-06-18/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 **         **Regulation FD Disclosure.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-18","source_url":"https://www.sec.gov/Archives/edgar/data/925741/0001437749-26-021041-index.html","accession_number":"0001437749-26-021041","cik":"0000925741","ticker":"BCDA","issuer_name":"BioCardia, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/925741/0001437749-26-021041-index.html","primary_entity_key":"0000925741","primary_entity_name":"BioCardia, Inc."},"word_count":138,"has_tables":true,"body_markdown":"**Item 7.01**         **Regulation FD Disclosure.**\n\n \n\nOn June 18, 2026, BioCardia, Inc. issued a press release containing its letter to shareholders, which provides an update on the Company’s business strategy, top priorities, and business development opportunities. A copy of the press release is attached hereto as Exhibit 99.1 to this current report on Form 8-K.\n\n \n\nThe information furnished pursuant to this Item 7.01, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under that section, nor shall it be deemed to be incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise expressly set forth by specific reference in such filing."}